After CEO’s Abrupt Resignation, Teva Management Emphasizes Stability
Executive Summary
A day after announcing the abrupt resignation of CEO Jeremy Levin, Teva’s management emphasized that the company’s current strategy would continue, including plans for dealing with ongoing pressures from Copaxone’s loss of exclusivity, and under-performance of the European generics businesses. Teva hoped to persuade rattled investors of its steady road to growth.
You may also be interested in...
Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?
Wall Street is mixed on whether Teva’s newly approved three-times-weekly formulation will protect its MS blockbuster franchise.
J.P. Morgan Notebook: Wednesday, January 15
We bring you news and notes from the third day of the 2014 J.P. Morgan Healthcare conference, which includes highlights from Genentech, Teva, Sarepta, and new accelerator StartUp Health.
People In The News: Former Federal Officials On The Move; Changes At Aurinia, Neo, Mallinckrodt, Lilly, And More
Former FDA Commissioner and CMS Administrator Mark McClellan joins the Johnson & Johnson board; former CMS officials Larry Kocot, Mark Hamelburg and Thomas Hutchinson join law firm Epstein Becker & Green; ONCHIT head Farzad Mostashari heads to Brookings; Aurinia names Glickman acting CEO; more personnel moves in this month’s column.